Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
The purpose of this study is to show that the use of low volume iso-osmolar non-ionic radio contrast medium (30 cc) in a thoracic CT Scanning procedure in a selected group of patients with chronic kidney disease (CKD) will avoid contrast induced nephropathy (CIN) in comparison to a similar group of patients with CKD who receive no contrast medium..
Checked against the public recordLast updated Nov 28, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- VA Greater Los Angeles Healthcare System
- Interventions being studied
- Drug: Low Volume iso-osmolar non-ionic radio contrast medium; Drug: Acetylcysteine Inhalation; Drug: Sodium Bicarbonate Solution; Procedure: 64-MDCT Scanning
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subjects with documented stable Chronic Kidney Disease (CKD) defined as a stable eGFR 16-60 ml/min/m\^2 for ≥ 12 months; and * Referred to CT scanning procedure to evaluate pulmonary embolism, pulmonary malignancy, acute aortic syndromes, or renal artery stenosis. Exclusion Criteria: * CKD Stages 1, 2 and 5 * Stage 3-4 congestive heart failure (CHF) * Irregular supraventricular tachycardia * Allergic to iodinated Radio Contrast Medium (RCM) * Allergic to Mucomyst * Pregnancy * Evidence of acute renal failure (ARF) * Serum bicarbonate either less than 20 meq/L or greater than 35 meq/L * Hydration with a bicarbonate solution is contraindicated or considered unsafe by the subject's caring physicians
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- VA Greater Los Angeles Healthcare SystemLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 28, 2017. Always confirm current availability with the study team.